Keyword search
Filter results by
Search HelpKeyword(s)
Subject
Survey or statistical program
Results
All (7)
All (7) ((7 results))
- Articles and reports: 88F0006X2005009Description:
The main indicators of biotechnology activities in Canada are presented in this article. The data are from the 2003 Biotechnology Use and Development Survey. Within the last few years, except for the number of employees with biotechnology-related responsibilities that remained stable, an increase in all the indicators was noticed. For example, the number of innovative firms involved in biotechnology activities rose from 375 in 2001 to 490 in 2003 and biotechnology revenues rose from $3.6 billion to $3.8 billion between 2001 and 2003. Also, biotechnology R&D spending increased by 11% between 2001 and 2003 and the amount of capital raised for biotechnology was up 73% during this period.
Release date: 2005-04-27 - Articles and reports: 88F0006X2004017Description:
Using data from the 1997 Biotechnology Firm Survey and the 1999 and 2001 cycles of the Biotechnology Use and Development Survey, this article portrays the evolution of key indicators of Canadian biotechnology companies from 1997 to 2001.
Release date: 2004-10-22 - Articles and reports: 88F0006X2003005Description:
The main indicators of biotechnology activities in Canada are presented in this article. The data are from the 2001 Biotechnology Use and Development Survey. Within the last few years, except for the amount of financing capital raised, an increase in all the indicators was noticed. For example, the number of innovative firms involved in biotechnology activities rose from 358 in 1999 to 375 in 2001. The Human Health sector outpaces all the other sectors in terms of the number of firms, human resources, biotechnology revenues, biotechnology research and development expenditures, amount of financing capital raised, and the number of products in the pipeline. Contrary to medium-sized and large firms where the personnel is more homogenous, small firms employ mostly highly-qualified workers. The 2001 data show a maturing trend in small firms. Most firms could not hire enough people to fill all their vacancies (estimated at 953 positions in Canada) for the 2001 year.
Release date: 2003-03-28 - Articles and reports: 88-003-X20030016475Geography: CanadaDescription:
Data from the 2001 Biotechnology Use and Development Survey show that human resources in biotechnology increased substantially between 1999 and 2001. In this article, we attempt to answer two questions: What are the characteristics of the human resources engaged in the biotechnology field in Canada? Moreover, what are the main factors that contributed to the growth of these human resources in 2001?
Release date: 2003-02-18 - Articles and reports: 88F0006X2002003Description:
This is the final of three papers providing data and an overview of the results of the Biotechnology Use and Development Survey - 1999. Readers are encouraged to use the data. The next edition of the Biotechnology Use and Development Survey - 2001 is expected to be administered in the spring of 2002 with results available early in 2003.
Release date: 2002-03-28 - 6. Canadian Biotechnology Industrial Activities: Features from the 1997 Biotechnology Survey ArchivedArticles and reports: 88F0006X2001012Description:
As of 1997, Canadian biotech industry was made of 282 core firms. Of these, 214 were small firms with less than 50 employees, 37 were medium firms with 51 to 150 employees, and 31 were large firms with over 150 employees. They earned $813 million from biotech products sales, $311 million of which were from exports. They employed 9,000 people in biotech related activities and had 8,924 products at all stages of development. Private placements, venture capital and labour sponsored funds were these firms main sources of financing capital. Access to capital was the most serious obstacle faced by the biotech firms in 1997. Marketing and distribution were their major reasons for entertaining strategic alliances, while universities were their most preferred R&D partners.
Release date: 2001-09-25 - Articles and reports: 88F0006X2001011Description:
This paper provides a summary of the strategies and business practices of biotechnology firms, and information on the business environment faced by these firms. These issues, considered in conjunction with information on revenue, research and development, import and export, product pipeline and human resources characteristics of biotechnology firms, contribute to a more comprehensive portrait of the biotechnology sector in Canada.
Release date: 2001-08-28
Data (0)
Data (0) (0 results)
No content available at this time.
Analysis (7)
Analysis (7) ((7 results))
- Articles and reports: 88F0006X2005009Description:
The main indicators of biotechnology activities in Canada are presented in this article. The data are from the 2003 Biotechnology Use and Development Survey. Within the last few years, except for the number of employees with biotechnology-related responsibilities that remained stable, an increase in all the indicators was noticed. For example, the number of innovative firms involved in biotechnology activities rose from 375 in 2001 to 490 in 2003 and biotechnology revenues rose from $3.6 billion to $3.8 billion between 2001 and 2003. Also, biotechnology R&D spending increased by 11% between 2001 and 2003 and the amount of capital raised for biotechnology was up 73% during this period.
Release date: 2005-04-27 - Articles and reports: 88F0006X2004017Description:
Using data from the 1997 Biotechnology Firm Survey and the 1999 and 2001 cycles of the Biotechnology Use and Development Survey, this article portrays the evolution of key indicators of Canadian biotechnology companies from 1997 to 2001.
Release date: 2004-10-22 - Articles and reports: 88F0006X2003005Description:
The main indicators of biotechnology activities in Canada are presented in this article. The data are from the 2001 Biotechnology Use and Development Survey. Within the last few years, except for the amount of financing capital raised, an increase in all the indicators was noticed. For example, the number of innovative firms involved in biotechnology activities rose from 358 in 1999 to 375 in 2001. The Human Health sector outpaces all the other sectors in terms of the number of firms, human resources, biotechnology revenues, biotechnology research and development expenditures, amount of financing capital raised, and the number of products in the pipeline. Contrary to medium-sized and large firms where the personnel is more homogenous, small firms employ mostly highly-qualified workers. The 2001 data show a maturing trend in small firms. Most firms could not hire enough people to fill all their vacancies (estimated at 953 positions in Canada) for the 2001 year.
Release date: 2003-03-28 - Articles and reports: 88-003-X20030016475Geography: CanadaDescription:
Data from the 2001 Biotechnology Use and Development Survey show that human resources in biotechnology increased substantially between 1999 and 2001. In this article, we attempt to answer two questions: What are the characteristics of the human resources engaged in the biotechnology field in Canada? Moreover, what are the main factors that contributed to the growth of these human resources in 2001?
Release date: 2003-02-18 - Articles and reports: 88F0006X2002003Description:
This is the final of three papers providing data and an overview of the results of the Biotechnology Use and Development Survey - 1999. Readers are encouraged to use the data. The next edition of the Biotechnology Use and Development Survey - 2001 is expected to be administered in the spring of 2002 with results available early in 2003.
Release date: 2002-03-28 - 6. Canadian Biotechnology Industrial Activities: Features from the 1997 Biotechnology Survey ArchivedArticles and reports: 88F0006X2001012Description:
As of 1997, Canadian biotech industry was made of 282 core firms. Of these, 214 were small firms with less than 50 employees, 37 were medium firms with 51 to 150 employees, and 31 were large firms with over 150 employees. They earned $813 million from biotech products sales, $311 million of which were from exports. They employed 9,000 people in biotech related activities and had 8,924 products at all stages of development. Private placements, venture capital and labour sponsored funds were these firms main sources of financing capital. Access to capital was the most serious obstacle faced by the biotech firms in 1997. Marketing and distribution were their major reasons for entertaining strategic alliances, while universities were their most preferred R&D partners.
Release date: 2001-09-25 - Articles and reports: 88F0006X2001011Description:
This paper provides a summary of the strategies and business practices of biotechnology firms, and information on the business environment faced by these firms. These issues, considered in conjunction with information on revenue, research and development, import and export, product pipeline and human resources characteristics of biotechnology firms, contribute to a more comprehensive portrait of the biotechnology sector in Canada.
Release date: 2001-08-28
Reference (0)
Reference (0) (0 results)
No content available at this time.
- Date modified: